Annonymous qoute from an annomymous boss at my annonymouse biotech job.
"We can't use that control because it might not work out how we want it to. If it casts a shadow over our drug candidate we're screwed."
Ah the joy of science.
And now for a countdown of some of the consequences for leaving out proper controls.
Point Therapeutics (POTP) Cuts 76% of Work Force. Recent interim clinical results led the Company's Independent Monitoring Committee to recommend stopping the Company's two Phase 3 talabostat studies as a potential treatment for patients in advanced non-small cell lung cancer, and the talabostat clinical development program was subsequently put on clinical hold by the FDA.
ImClone Systems Incorporated (IMCL) Says Erbitux Fails in Lung Cancer Trial More...
Endo Pharmaceuticals (ENDP) Says Patch Fails 2 Late-Stage Trials; Shares Fall More...
Antisoma PLC (ASM.L) and Novartis Corporation (NVS) Drug Fails in Ovarian Cancer More...
Amgen (AMGN) (Jobs) and Daiichi Sankyo, Inc. Reach Deal on Bone Antibody More...
I threw in the Amgen story because I used to work with RANK ligand and one of the lead scientists at Amgen on the RANK ligand project. Amgen sent this scientist packing back in 2001. They didn't believe in the drug. This would never stop them from making a deal however. Good people.
Controls in the early stages of research would only put us out of work faster. Sorry cancer patients but we're going to keep trying to make these old drugs work. We don't have the time nor money to find new ones. Keep your fingers crossed. We do the same things when working without proper controls.
No comments:
Post a Comment